Immatics N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMTX research report →
Range $16 – $28
Price Chart
About the company
Immatics N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States.
- CEO
- Harpreet Singh
- IPO
- 2018
- Employees
- 589
- HQ
- Tübingen, BW, DE
Get TickerSpark's AI analysis on IMTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.15B
- P/E
- -4.60
- PEG
- 0.05
- P/S
- 23.45
- P/B
- 2.50
- EV/EBITDA
- -3.83
- Div Yield
- 0.00%
- Gross Margin
- 77.79%
- Op Margin
- -544.48%
- Net Margin
- -495.95%
- ROE
- -45.39%
- ROIC
- -52.79%
Latest fiscal year · YoY change
- Revenue
- $48.27M-69.0%
- Gross Profit
- $48.27M-69.0%
- Op Income
- $-182,016,000
- Net Income
- $-196,447,000-1390.9%
- EPS
- $-1.54-1200.0%
- OCF Growth
- -7.4%
- FCF Growth
- -0.8%
- 52W High
- $12.41
- 52W Low
- $5.05
- 50D MA
- $9.46
- 200D MA
- $10.03
- Beta
- 1.32
- RSI (14)
- 37
- Avg Volume
- 463.05K
No earnings-call transcripts are available for IMTX yet.
- Free Float
- 83.7%
- Shares Outstanding
- 134.10M
- Float Shares
- 112.20M
of shares held by institutions
80 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 690.76K | ▲ 32.37K |
| Aquilo Capital Management, LLC | 304.90K | ▼ 69.00K |
| Gratus Capital LLC | 205.39K | ▲ 10.11K |
Held by 10 ETFs
Biggest fund positions in IMTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Pepin James Nelson | other | 181,200 |
| Aug 14, 26 | Pepin James Nelson | other | 43,800 |
| Jul 20, 26 | Pepin James Nelson | other | 0 |
| Jun 16, 26 | Stone Adam Leo | other | 48,000 |
| Jun 16, 26 | REICIN ALISE | other | 48,000 |
| Jun 16, 26 | ATIEH MICHAEL G | other | 48,000 |
| Jun 16, 26 | Carter Paul Rutherford | other | 48,000 |
| Jun 16, 26 | Forster Eliot | other | 48,000 |
| Jun 16, 26 | Chambre Peter Alan | other | 48,000 |
| Jun 16, 26 | Mason Heather L | other | 48,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMTX coverage
Recent articles, reports, and earnings notes.
No research on IMTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMTX report →Immatics Announces Second Quarter 2026 Financial Results and Business Update
globenewswire.com · Aug 18
Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80
defenseworld.net · Jul 30
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
globenewswire.com · Jul 17
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
globenewswire.com · Jul 17
Immatics: PRAME Is Becoming More Than A Single-Asset Story
seekingalpha.com · Jun 16
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
globenewswire.com · Jun 1
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
globenewswire.com · Jun 1
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
globenewswire.com · May 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.